Skip to content
Screener

Castle Biosciences CSTL Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$84.2MBeat by $5.0M
EPS-$0.49In line
Revenue estimate$79.2M
EPS estimate-$0.49

Next report

Nov 2, 2026 (in a month)
Revenue estimate$92.1M
EPS estimate-$0.38

Financials

Q1 2026

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$729.9M+27.9%
Enterprise value$702.86M+38.6%
P/S2.1×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Segments

By product

See full
Non-Dermatologic$42.6M+70.1%
Dermatologic$41.1M-34.7%

By segment

See full
Reportable Segment$83.7M-4.9%

FAQ

When did Castle Biosciences report Q1 2026 earnings?
Castle Biosciences (CSTL) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Castle Biosciences's Q1 2026 revenue and EPS?
Castle Biosciences reported revenue of $84.2M and eps of $-0.49 for Q1 2026.
Did Castle Biosciences beat estimates in Q1 2026?
Revenue beat the consensus estimate of $79.2M by $5.0M. EPS beat the consensus estimate of $-0.49 by $0.00.
How did Castle Biosciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 4.3% from $88.0M a year earlier and eps declined 145.0% from $-0.20.
Where can I find Castle Biosciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-031255) and the 10-Q periodic report (0001628280-26-031263) directly on SEC EDGAR. The filing index links above go to sec.gov.